Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: Results of a randomised controlled trial (VISARA)

Annals of the Rheumatic Diseases

Volumn 74, Issue 5, 2015, Pages 818-822

  Bingham, Clifton O ^a   Rizzo, Warren ^b   Kivitz, Alan ^c   Hassanali, Azra ^d   Upmanyu, Ruchi ^e   Klearman, Micki ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Advanced Arthritis Care and Research   (United States)

^c Altoona Center for Clinical Research   (United States)

^d GENENTECH INC   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMORAL IMMUNITY; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VACCINATION; ADOLESCENT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS; TETANUS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; METHOTREXATE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TETANUS; TETANUS TOXOID; YOUNG ADULT;

EID: 84926465540     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204427     Document Type: Article

References (19)

1. Smitten AL, Choi HK, Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35:387-93.
2. Singh JA, Furst DE, Bharat A, et al 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64:625-39.
3. van Assen S., Agmon-Levin N, Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70:414-22.
4. Kapetanovic MC, Saxne T, Sjoholm A., et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:106-11.
5. Elkayam O, Caspi D, Reitblatt T., et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33:283-8.
6. Bingham CO III, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64-74.
7. Mihara M, Kasutani K, Okazaki M., et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5:1731-40.
8. Roldan E, Brieva JA Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol 1991; 21:2671-7.
9. Muraguchi A, Hirano T, Tang B., et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-44.
10. Muhammad K, Roll P, Seibold T., et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 2011; 70:1507-10.
11. Morse L, Chen D, Franklin D., et al. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 1997; 6:47-56.
12. Kishimoto T, Taga T, Yamasaki K., et al. Normal and abnormal regulation of human B cell differentiation by a new cytokine, BSF2/IL-6. Adv Exp Med Biol 1989; 254:135-43.
13. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49:15-24.
14. Mori S, Ueki Y, Hirakata N., et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71:2006-10.
15. Mori S, Ueki Y, Akeda Y., et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013; 72:1362-6.
16. Arnett FC, Edworthy SM, Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
17. Mease PJ, Ritchlin CT, Martin R.W., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31:1356-61.
18. Actemra® (tocilizumab injection, for intravenous infusion). South San Francisco, CA: Genentech, Inc., 2011.
19. RoActemra 20 mg/mL concentrate for solution for infusion. Hertfordshire, UK: Roche Registration Ltd, 2010.